Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Studie mit Pasritamig und Docetaxel versus Docetaxel bei Teilnehmern mit metastasiertem kastrationsresistentem Prostatakrebs (KLK2-PASenger)

2. November 2026 aktualisiert von: Janssen Research & Development, LLC

Eine randomisierte Phase-3-Studie mit offenem Label zur Untersuchung von Pasritamig (JNJ-78278343), einem T-Zell-umlenkenden Wirkstoff gegen humanes Kallikrein 2, mit Docetaxel versus Docetaxel bei metastasierendem kastrationsresistentem Prostatakrebs

The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or death due to any cause) when compared to treatment with docetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; a cancer of prostate, a male reproductive gland found below the bladder, that grows despite low levels of male hormones).

Studienübersicht

Studientyp

Interventionell

Einschreibung (Geschätzt)

800

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

      • Heidelberg, Australien, 3084
        • Rekrutierung
        • Warringal Private Hospital
      • Kurralta Park, Australien, 5037
        • Rekrutierung
        • Icon Cancer Centre Kurralta Park
      • Melbourne, Australien, 3000
        • Rekrutierung
        • Peter MacCallum Cancer Centre
      • Wahroonga, Australien, 2076
        • Rekrutierung
        • Sydney Adventist Hospital
      • Woolloongabba, Australien, 4102
        • Rekrutierung
        • Princess Alexandra Hospital
      • Aalst, Belgien, 9300
        • Rekrutierung
        • AZORG campus Aalst Moorselbaan
      • Antwerp, Belgien, 2610
        • Rekrutierung
        • ZAS Augustinus
      • Ghent, Belgien, 9000
        • Rekrutierung
        • AZ Maria Middelares
      • La Louvière, Belgien, 7100
        • Rekrutierung
        • Chu Helora Hospital La Louviere Site Jolimont
      • Liège, Belgien, 4000
        • Rekrutierung
        • CHC MontLegia
      • Bauru, Brasilien, 17033-495
        • Rekrutierung
        • NAIC Nair Antunes Instituto do Cancer
      • Natal, Brasilien, 59062 000
        • Rekrutierung
        • Liga Norte Riograndense Contra O Cancer
      • Santa Cruz do Sul, Brasilien, 96835-100
        • Rekrutierung
        • Hospital Ana Nery Santa Cruz do Sul
      • Santo André, Brasilien, 09060 870
        • Rekrutierung
        • CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
      • São Paulo, Brasilien, 01243 020
        • Rekrutierung
        • Hospital Samaritano de Sao Paulo
      • Beijing, China, 100142
        • Rekrutierung
        • Beijing Cancer Hospital
      • Beijing, China, 100034
        • Rekrutierung
        • Peking University First Hospital
      • Beijing, China, 101100
        • Rekrutierung
        • Beijing Luhe Hospital, Capital Medical University
      • Chengdu, China, 610014
        • Rekrutierung
        • The Third People's Hospital of Chengdu
      • Chengdu, China, 610041
        • Rekrutierung
        • West China Hospital Sichuan University
      • Chongqing, China, 400030
        • Rekrutierung
        • Chongqing University Cancer Hospital
      • Guangzhou, China, 510120
        • Rekrutierung
        • The First Affiliated Hospital of Guangzhou Medical University
      • Guangzhou, China, 510060
        • Rekrutierung
        • Sun Yat Sen University Cancer Center
      • Hangzhou, China, 310009
        • Rekrutierung
        • Sir Run Run Shaw Hospital Zhejiang University School of Medicine
      • Nanjing, China, 210009
        • Rekrutierung
        • Nanjing Drum Tower Hospital
      • Shanghai, China, 200080
        • Rekrutierung
        • Shanghai General Hospital
      • Shanghai, China, 200031
        • Rekrutierung
        • Huashan Hospital Fudan University
      • Shanghai, China, 200082
        • Rekrutierung
        • Xinhua hospital,Shanghai Jiaotong University
      • Tianjin, China, 300211
        • Rekrutierung
        • The Second Hospital Of Tianjin Medical University
      • Wuhan, China, 430014
        • Rekrutierung
        • The Central Hospital of Wuhan
      • Xi'an, China, 710061
        • Rekrutierung
        • The First Affiliated Hospital of Xian Jiaotong University
      • Dresden, Deutschland, 01307
        • Rekrutierung
        • Universitatsklinikum Carl Gustav Carus Dresden
      • Duisburg, Deutschland, 47169
        • Rekrutierung
        • Urologicum Duisburg
      • Essen, Deutschland, 45147
        • Rekrutierung
        • Universitaetsklinikum Essen
      • Hamburg, Deutschland, 20246
        • Rekrutierung
        • Martini-Klinik am Universitätsklinikum Hamburg-Eppendorf Urologie
      • München, Deutschland, 81675
        • Rekrutierung
        • Klinikum rechts der Isar an der Technischen Universitat Munchen
      • Nürtingen, Deutschland, 72622
        • Rekrutierung
        • Studienpraxis Urologie Drs. Feyerabend
      • Bordeaux, Frankreich, 33076
        • Rekrutierung
        • Institut Bergonie
      • Clermont-Ferrand, Frankreich, 63011
        • Rekrutierung
        • Centre Jean Perrin
      • Lille, Frankreich, 59000
        • Rekrutierung
        • Centre Oscar Lambret
      • Lyon, Frankreich, 69008
        • Rekrutierung
        • Centre Leon Berard
      • Nîmes, Frankreich, 30900
        • Rekrutierung
        • Groupe Hospitalo-Universitaire Carémeau
      • Paris, Frankreich, 75908
        • Rekrutierung
        • Hopital Europeen Georges-Pompidou
      • Rennes, Frankreich, 35062
        • Rekrutierung
        • Centre Eugene Marquis
      • Villejuif, Frankreich, 94800
        • Rekrutierung
        • Gustave Roussy
      • Florence, Italien, 50134
        • Rekrutierung
        • Azienda Ospedaliero Universitaria Careggi
      • Localita La Schiana Pozzuoli, Italien, 80078
        • Rekrutierung
        • ASL Napoli 2 Nord-SM delle Grazie Hospital
      • Milan, Italien, 20141
        • Rekrutierung
        • Istituto Europeo di Oncologia
      • Milan, Italien, 20132
        • Rekrutierung
        • IRCCS Ospedale San Raffaele
      • Roma, Italien, 00144
        • Rekrutierung
        • Istituto Nazionale Tumori Regina Elena
      • Torino, Italien, 10126
        • Rekrutierung
        • Azienda Ospedaliera Universitaria Citta della Salute e della Scienza di Torino
      • Bunkyō City, Japan, 113 8431
        • Rekrutierung
        • Juntendo University Hospital
      • Hirakata, Japan, 573-1191
        • Rekrutierung
        • Kansai Medical University Hospital
      • Kanazawa, Japan, 920 8641
        • Rekrutierung
        • Kanazawa University Hospital
      • Kobe, Japan, 650 0017
        • Rekrutierung
        • Kobe University Hospital
      • Sagamihara, Japan, 252-0375
        • Rekrutierung
        • Kitasato University Hospital
      • Sunto Gun, Japan, 411 8777
        • Rekrutierung
        • Shizuoka Cancer Center
      • Yokohama, Japan, 232 0024
        • Rekrutierung
        • Yokohama City University Medical Center
    • British Columbia
      • Vancouver, British Columbia, Kanada, V5Z4E6
        • Rekrutierung
        • British Columbia Cancer Agency
      • Victoria, British Columbia, Kanada, V8R 6V5
        • Rekrutierung
        • British Columbia Cancer Agency Vancouver Island Centre
    • Ontario
      • Ottawa, Ontario, Kanada, K1H 8L6
        • Rekrutierung
        • The Ottawa Hospital Cancer Centre
      • Toronto, Ontario, Kanada, M5G 2C4
        • Rekrutierung
        • Princess Margaret Cancer Centre
    • Quebec
      • Montreal, Quebec, Kanada, H2X 0A9
        • Rekrutierung
        • Centre de Recherche du CHUM
      • Québec, Quebec, Kanada, G1R 2J6
        • Rekrutierung
        • CHU de Quebec Universite Laval
      • Kota Kinabalu, Malaysia, 88996
        • Rekrutierung
        • Hospital Wanita dan Kanak-Kanak Sabah
      • Kuala Lumpur, Malaysia, 59100
        • Rekrutierung
        • University Malaya Medical Centre
      • Kuala Lumpur, Malaysia, 50586
        • Rekrutierung
        • Hospital Kuala Lumpur
      • Kuala Lumpur, Malaysia, 59100
        • Rekrutierung
        • Pantai Hospital Kuala Lumpur
      • Kuching, Malaysia, 93586
        • Rekrutierung
        • Hospital Umum Sarawak
      • San Juan, Puerto Rico, 935
        • Rekrutierung
        • Pan American Center for Oncology Trials LLC
      • Badalona, Spanien, 08916
        • Rekrutierung
        • Hosp. Univ. Germans Trias I Pujol
      • Madrid, Spanien, 28034
        • Rekrutierung
        • Hosp. Univ. Ramon Y Cajal
      • Madrid, Spanien, 28041
        • Rekrutierung
        • Hosp. Univ. 12 de Octubre
      • Murcia, Spanien, 30008
        • Rekrutierung
        • Hosp. Gral. Univ. J.M. Morales Meseguer
      • Seville, Spanien, 41009
        • Rekrutierung
        • Hosp. Virgen Macarena
      • Valencia, Spanien, 46014
        • Rekrutierung
        • Hosp. Gral. Univ. Valencia
      • Zaragoza, Spanien, 50009
        • Rekrutierung
        • Hosp. Clinico Univ. Lozano Blesa
      • Goyang-si, Südkorea, 10408
        • Rekrutierung
        • National Cancer Center
      • Seoul, Südkorea, 05505
        • Rekrutierung
        • Asan Medical Center
      • Seoul, Südkorea, 06351
        • Rekrutierung
        • Samsung Medical Center
      • Seoul, Südkorea, 03722
        • Rekrutierung
        • Severance Hospital Yonsei University Health System
      • Seoul, Südkorea, 06591
        • Rekrutierung
        • The Catholic University of Korea Seoul St Marys Hospital
      • Taichung, Taiwan, 435
        • Rekrutierung
        • Tungs' Taichung MetroHarbor Hospital
      • Taichung, Taiwan, 404
        • Rekrutierung
        • China Medical University Hospital
      • Taichung, Taiwan, 407219
        • Rekrutierung
        • Taichung Veterans General Hospital
      • Tainan, Taiwan, 704
        • Rekrutierung
        • National Cheng Kung University Hospital
      • Taoyuan, Taiwan, 333
        • Rekrutierung
        • Linkou Chang Gung Memorial Hospital
      • Adana, Türkei (türkiye), 01170
        • Rekrutierung
        • Adana City Hospital
      • Ankara, Türkei (türkiye), 06010
        • Rekrutierung
        • Gulhane Training and Research Hospital
      • Ankara, Türkei (türkiye), 06100
        • Rekrutierung
        • Ankara University Medical Faculty
      • Istanbul, Türkei (türkiye), 34096
        • Rekrutierung
        • Istanbul University Cerrahpasa tip Fakultesi
      • Istanbul, Türkei (türkiye), 34147
        • Rekrutierung
        • Koc Universitesi Hastanesi
      • Izmir, Türkei (türkiye), 35170
        • Rekrutierung
        • Medicana International Izmir
    • Arizona
      • Chandler, Arizona, Vereinigte Staaten, 85225
        • Rekrutierung
        • Arizona Clinical Trials
    • Arkansas
      • Little Rock, Arkansas, Vereinigte Staaten, 72211
        • Rekrutierung
        • Arkansas Urology
      • Springdale, Arkansas, Vereinigte Staaten, 72762
        • Rekrutierung
        • Highlands Oncology Group
    • California
      • Fountain Valley, California, Vereinigte Staaten, 92708
        • Rekrutierung
        • MemorialCare Orange Coast Medical Center
      • La Jolla, California, Vereinigte Staaten, 92037
        • Rekrutierung
        • University Of California San Diego
      • Los Alamitos, California, Vereinigte Staaten, 90720
        • Rekrutierung
        • Cancer and Blood Specialty Clinic
      • Los Angeles, California, Vereinigte Staaten, 90033
        • Rekrutierung
        • USC Norris Comprehensive Cancer Center
      • Los Angeles, California, Vereinigte Staaten, 90095
        • Rekrutierung
        • Ronald Reagan UCLA Medical Center
      • Los Angeles, California, Vereinigte Staaten, 90067
        • Rekrutierung
        • Valkyrie Clinical Trials
      • Riverside, California, Vereinigte Staaten, 92505
        • Rekrutierung
        • Kaiser Permanente Southern California
      • San Diego, California, Vereinigte Staaten, 92123
        • Rekrutierung
        • Sharp Center for Research
      • Santa Monica, California, Vereinigte Staaten, 90404
        • Rekrutierung
        • Providence Saint John s Health Center
    • Colorado
      • Aurora, Colorado, Vereinigte Staaten, 80012
        • Rekrutierung
        • Rocky Mountain Cancer Centers
      • Denver, Colorado, Vereinigte Staaten, 80210
        • Rekrutierung
        • AdventHealth Porter Oncology Research
      • Edwards, Colorado, Vereinigte Staaten, 81632
        • Rekrutierung
        • Vail Health Shaw Cancer Center
      • Grand Junction, Colorado, Vereinigte Staaten, 81505
        • Rekrutierung
        • Grand Valley Oncology
      • Lakewood, Colorado, Vereinigte Staaten, 80228
        • Rekrutierung
        • Colorado Clinical Research
    • Florida
      • Orlando, Florida, Vereinigte Staaten, 32803
        • Rekrutierung
        • AdventHealth Orlando
      • Pembroke Pines, Florida, Vereinigte Staaten, 33026
        • Rekrutierung
        • Memorial Cancer Institute
      • Sarasota, Florida, Vereinigte Staaten, 34232
        • Rekrutierung
        • Florida Cancer Specialists
    • Georgia
      • Atlanta, Georgia, Vereinigte Staaten, 30322
        • Rekrutierung
        • Winship Cancer Institute Emory University
    • Illinois
      • Lisle, Illinois, Vereinigte Staaten, 60532
        • Rekrutierung
        • Duly Health and Care
    • Kansas
      • Wichita, Kansas, Vereinigte Staaten, 67214
        • Rekrutierung
        • Cancer Center of Kansas Heritage Plaza Medical Building
    • Kentucky
      • Edgewood, Kentucky, Vereinigte Staaten, 41017
        • Rekrutierung
        • St Elizabeth Healthcare
      • Louisville, Kentucky, Vereinigte Staaten, 40207
        • Rekrutierung
        • Norton Cancer Institute
    • Louisiana
      • Metairie, Louisiana, Vereinigte Staaten, 70006
        • Rekrutierung
        • East Jefferson General Hospital
    • Maryland
      • Baltimore, Maryland, Vereinigte Staaten, 21287
        • Rekrutierung
        • Johns Hopkins Hospital
      • Baltimore, Maryland, Vereinigte Staaten, 21201
        • Rekrutierung
        • University of Maryland
      • Baltimore, Maryland, Vereinigte Staaten, 21287
        • Rekrutierung
        • Johns Hopkins Medical Institutions
      • Bethesda, Maryland, Vereinigte Staaten, 20817
        • Rekrutierung
        • Center for Cancer and Blood Disorders
      • Towson, Maryland, Vereinigte Staaten, 21204
        • Rekrutierung
        • Chesapeake Urology Research Associates
    • Massachusetts
      • Boston, Massachusetts, Vereinigte Staaten, 02114
        • Rekrutierung
        • Massachusetts General
    • Michigan
      • Sterling Heights, Michigan, Vereinigte Staaten, 48314
        • Rekrutierung
        • Profound Research LLC at Cancer and Leukemia Center
    • Minnesota
      • Saint Louis Park, Minnesota, Vereinigte Staaten, 55426
        • Rekrutierung
        • HealthPartners Frauenshuh Cancer Center CRC West
      • Saint Paul, Minnesota, Vereinigte Staaten, 55101
        • Rekrutierung
        • HealthPartners Cancer Center at Regions Hospital CRC East
    • Mississippi
      • Jackson, Mississippi, Vereinigte Staaten, 39216
        • Rekrutierung
        • University of Mississippi Medical Center
    • Missouri
      • St Louis, Missouri, Vereinigte Staaten, 63110
        • Rekrutierung
        • Washington University
    • Nebraska
      • Lincoln, Nebraska, Vereinigte Staaten, 68506
        • Rekrutierung
        • NHO Revive Research Institute, LLC
    • New Jersey
      • Camden, New Jersey, Vereinigte Staaten, 08103
        • Rekrutierung
        • Cooper Health System MD Anderson Cancer Center at Cooper
      • East Brunswick, New Jersey, Vereinigte Staaten, 08816
        • Rekrutierung
        • Astera Cancer Care
      • New Brunswick, New Jersey, Vereinigte Staaten, 08901
        • Rekrutierung
        • Rutgers Cancer Institute of New Jersey
    • New York
      • Mineola, New York, Vereinigte Staaten, 11501
        • Rekrutierung
        • Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island
      • New York, New York, Vereinigte Staaten, 10016
        • Rekrutierung
        • NYU Langone Health Laura and Isaac Perlmutter Cancer Center
      • The Bronx, New York, Vereinigte Staaten, 10461
        • Rekrutierung
        • Montefiore Medical Center
    • North Carolina
      • Durham, North Carolina, Vereinigte Staaten, 27710
        • Rekrutierung
        • Duke University Medical Center
    • Ohio
      • Canton, Ohio, Vereinigte Staaten, 44718
        • Rekrutierung
        • Gabrail Cancer Center
      • Cincinnati, Ohio, Vereinigte Staaten, 45219
        • Rekrutierung
        • University of Cincinnati
      • Cleveland, Ohio, Vereinigte Staaten, 44109
        • Rekrutierung
        • Metrohealth Medical Center
    • Oregon
      • Springfield, Oregon, Vereinigte Staaten, 97477
        • Rekrutierung
        • Oregon Urology Institute
    • Pennsylvania
      • Allentown, Pennsylvania, Vereinigte Staaten, 18103
        • Rekrutierung
        • Lehigh Valley Hospital
      • Bala-Cynwyd, Pennsylvania, Vereinigte Staaten, 19004
        • Rekrutierung
        • MidLantic Urology
      • Hershey, Pennsylvania, Vereinigte Staaten, 17033
        • Rekrutierung
        • Penn State Milton S. Hershey Medical Center
      • Pittsburgh, Pennsylvania, Vereinigte Staaten, 15232
        • Rekrutierung
        • University Of Pittsburgh Medical Center UPMC Hillman Cancer Center
    • South Carolina
      • Myrtle Beach, South Carolina, Vereinigte Staaten, 29572
        • Rekrutierung
        • Carolina Urologic Research Center
    • South Dakota
      • Sioux Falls, South Dakota, Vereinigte Staaten, 57105
        • Rekrutierung
        • Avera Medical Group
      • Watertown, South Dakota, Vereinigte Staaten, 57201
        • Rekrutierung
        • Prairie Lakes Health Care System
    • Tennessee
      • Knoxville, Tennessee, Vereinigte Staaten, 37909
        • Rekrutierung
        • Tennessee Cancer Specialists
    • Texas
      • Austin, Texas, Vereinigte Staaten, 78731
        • Rekrutierung
        • Texas Oncology
      • Dallas, Texas, Vereinigte Staaten, 75390
        • Rekrutierung
        • UT Southwestern Medical Center
      • Houston, Texas, Vereinigte Staaten, 77027
        • Rekrutierung
        • Houston Metro Urology
      • Sugar Land, Texas, Vereinigte Staaten, 77479
        • Rekrutierung
        • Texas Oncology 1
      • The Woodlands, Texas, Vereinigte Staaten, 77380
        • Rekrutierung
        • Renovatio Clinical
    • Virginia
      • Fairfax, Virginia, Vereinigte Staaten, 22031
        • Rekrutierung
        • Virginia Cancer Specialists
    • Washington
      • Seattle, Washington, Vereinigte Staaten, 98109
        • Rekrutierung
        • Fred Hutchinson Cancer Research Center
      • Seattle, Washington, Vereinigte Staaten, 98109
        • Rekrutierung
        • Fred Hutch Cancer Center Sloan Clinic 2
      • Cardiff, Vereinigtes Königreich, CF14 2TL
        • Rekrutierung
        • Velindre Cancer Centre
      • Glasgow, Vereinigtes Königreich, G12 0YN
        • Rekrutierung
        • Beatson West Of Scotland Cancer Centre
      • London, Vereinigtes Königreich, EC1A 7BE
        • Rekrutierung
        • St Bartholomews Hospital
      • London, Vereinigtes Königreich, SW3 6JJ
        • Rekrutierung
        • The Royal Marsden NHS Trust
      • Newcastle upon Tyne, Vereinigtes Königreich, NE7 7DN
        • Rekrutierung
        • The Newcastle upon Tyne Hospitals NHS Trust - Freeman Hospit
      • Preston, Vereinigtes Königreich, PR2 9HT
        • Rekrutierung
        • Lancashire Teaching Hospitals NHS Foundation Trust Royal Preston Hospital
      • Sutton, Vereinigtes Königreich, SM2 5PT
        • Rekrutierung
        • Royal Marsden Hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion criteria:

  • Have histologically confirmed adenocarcinoma of the prostate
  • Have disease that is metastatic at the time of screening by computed tomography (CT) or magnetic resonance imaging (MRI) and 99m^Tc bone scan as determined by the investigator
  • Participants must receive ongoing androgen deprivation therapy (ADT) with a gonadotropin releasing hormone (GnRH) analog throughout the treatment or have had prior bilateral orchiectomy, and have serum testosterone less than or equal to (<=) 50 nanogram per deciliter (ng/dL) (<= 1.73 nanomoles per Liter [nmol/L]) at screening
  • Have progressed by PSA or CT/MRI or 99m^Tc bone scan on at least 1 novel androgen receptor pathway inhibition (ARPI) but no more than 2 different ARPI for any stage of disease. Must have discontinued ARPI before randomization into the study
  • Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1

Exclusion criteria:

  • Known history of either brain or leptomeningeal prostate cancer metastases
  • Participants with known breast cancer gene 1/2 (BRCA 1/2) mutations (germline or somatic) who have not received treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor, unless not available or contraindicated
  • Prior or concurrent second malignancy (other than the disease under study)
  • Received cytotoxic chemotherapy for prostate cancer in any setting
  • Received prior treatment with human kallikrein 2 (KLK-2) directed therapies

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Pasritamig+Docetaxel

Participants will receive pasritamig along with docetaxel until the end of treatment (EOT) visit or until radiographic disease progression is confirmed by blinded independent central review (BICR), or any other protocol defined criteria are met.

Pasritamig will be administered.

Andere Namen:
  • JNJ-78278343

Docetaxel will be administered.

Aktiver Komparator: Docetaxel

Participants will receive docetaxel along with prednisone/prednisolone as background medication.

Docetaxel will be administered.

Prednisone/Prednisolone will be administered.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Radiographic Progression-Free Survival (rPFS) by computed tomography (CT)/magnetic resonance imaging (MRI) or bone scan Assessed by Blinded Independent Central Review (BICR)
Zeitfenster: Up to approximately 1 years 10 months

rPFS by CT/MRI or bone scan is assessed by BICR and is defined as the time from the date of randomization to the first date of radiographic disease progression, or death due to any cause, whichever occurs first.

Up to approximately 1 years 10 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Overall Survival (OS)
Zeitfenster: Up to approximately 4 years 5 months

OS is defined as the time from the date of randomization to the date of death due to any cause.

Up to approximately 4 years 5 months
Time to Symptomatic Progression (TSP)
Zeitfenster: Up to approximately 4 years 5 months

TSP is defined as the time from the date of randomization to the date of the first occurrence of any of the following: the use of external beam radiation to relieve cancer-related symptoms, the need for tumor-related surgical intervention, other cancer-related procedures, cancer-related morbid events, and initiation of a new systemic anticancer therapy because of cancer symptoms.

Up to approximately 4 years 5 months
Time to Subsequent Therapy (TST)
Zeitfenster: Up to approximately 4 years 5 months

TST is defined as time from randomization to the initiation of any subsequent systemic anticancer therapy for prostate cancer

Up to approximately 4 years 5 months
Time to Skeletal-Related Event (TSRE)
Zeitfenster: Up to approximately 4 years 5 months

TSRE is defined as the time from the date of randomization to the date of first occurrence of any of the following (whichever occurs first): the use of external beam radiation therapy to relieve skeletal symptoms, the need for tumor-related orthopedic surgical intervention, the occurrence of new bone fractures (cancer-related; vertebral or non-vertebral) or the occurrence of tumor-related spinal cord compression.

Up to approximately 4 years 5 months
Objective Response Rate (ORR)
Zeitfenster: Up to approximately 4 years 5 months

ORR is defined as the proportion of participants who have measurable disease at baseline and have complete response (CR) or partial response (PR) or better by objective radiographic disease evaluation per response evaluation criteria in solid tumors (RECIST) version.1.1 response criteria and no bone progression as per prostate cancer working group 3 (PCWG3) as determined by the BICR.

Up to approximately 4 years 5 months
Duration of Response (DOR)
Zeitfenster: Up to approximately 4 years 5 months

DOR will be calculated among responders (PR or better) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the PCWG3 or RECIST version 1.1 response criteria, or death due to any cause, whichever occurs first.

Up to approximately 4 years 5 months
Time to Prostate-Specific Antigen (PSA) Progression
Zeitfenster: Up to approximately 4 years 5 months

Time to PSA progression is defined as the time from randomization to the first date of documented PSA progression per prostate cancer working group 3 (PCWG3) criteria. PSA progression is defined as: (1) After a decline from baseline, PSA increases greater than or equal to (>=) 25% and >=2 nanogram per milliliter (ng/mL) above the nadir, confirmed by a second value >=3 weeks later (that is, a confirmed rising trend), or (2) If there is no decline from baseline, PSA increases >=25% and >=2 ng/mL from baseline after 12 weeks

Up to approximately 4 years 5 months
Proportion of Participants Who Achieved Prostate-Specific Antigen (PSA) 50 Response
Zeitfenster: Up to approximately 4 years 5 months

PSA-50 response is defined as the proportion of participants with a reduction in blood concentration of PSA (ng/mL) to 50% from baseline, confirmed by a second value, at least 3 weeks apart.

Up to approximately 4 years 5 months
Proportion of Participants Who Achieved Prostate-Specific Antigen (PSA) 90 Response
Zeitfenster: Up to approximately 4 years 5 months

PSA-90 response is defined as the proportion of participants with a reduction in blood concentration of PSA (ng/mL) to 90% from baseline, confirmed by a second value, at least 3 weeks apart.

Up to approximately 4 years 5 months
Duration of PSA Response
Zeitfenster: Baseline and up to approximately 4 years 5 months

Duration of a PSA response is the time taken to achieve a PSA response that is decrease in PSA from baseline by >= 50%.

Baseline and up to approximately 4 years 5 months
Progression Free Survival After Subsequent Therapy (PFS2)
Zeitfenster: Up to approximately 4 years 5 months

PFS2 is defined as the time from randomization to the date of progression (radiographic, clinical, or PSA progression) on the first subsequent anti-cancer (second progression), or death from any cause, whichever comes first.

Up to approximately 4 years 5 months
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) by Severity
Zeitfenster: Up to approximately 4 years 5 months

An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. An SAE: results in death, is life-threatening, requires inpatient hospitalization or prolonging hospitalization, results in disability, is a congenital birth defect, is a suspected transmission of any infectious agent via a medicinal product, is indicating suicidal ideation, is medically important. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0. by using standard grades as follows: Grade 1: Mild; asymptomatic or mild symptoms; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; Grade 3: Severe but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; Grade 4: Life-threatening consequences; and Grade 5: Death related to AE.

Up to approximately 4 years 5 months
Number of Participants With Clinical Laboratory Abnormalities
Zeitfenster: Up to approximately 4 years 5 months

Participants with laboratory abnormalities (hematology, serum chemistry, coagulation, and tumor markers) will be reported.

Up to approximately 4 years 5 months
Change from Baseline in Health Related Quality of Life (HRQoL) as Assessed by Brief Pain Inventory-Short Form (BPI-SF)
Zeitfenster: Baseline up to approximately 4 years 5 months

The BPI-SF was developed to measure both intensity or severity of pain and pain interference with daily life dimensions. It measures pain intensity via 4 questions, that is, "pain at its worst in the last 24 hours", "pain at its least in the last 24 hours", "pain on the average", and "pain you have right now". The BPI-SF assesses how much pain has interfered with the following 7 activities: general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Higher score indicates more pain.

Baseline up to approximately 4 years 5 months
Change from Baseline in HRQoL as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Cancer Module (EORTC QLQ-C30) Scale Score
Zeitfenster: Baseline up to approximately 4 years 5 months

The EORTC QLQ-C30 - Version 3 is a self-administered, 30-item questionnaire measuring the health-related quality of life of participants with cancer. EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), a global health status / quality of life scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much". Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent". A high score for a functional scale represents a high level of functioning, whereas a high score for a symptom scale/single item represents a high level of symptom.

Baseline up to approximately 4 years 5 months
Change from Baseline in HRQoL as Assessed by EORTC Quality of Life Questionnaire-Prostate (EORTC QLQ-PR25) Scale Score
Zeitfenster: Baseline up to approximately 4 years 5 months

The EORTC QLQ-PR25 is a self-completed instrument was specifically designed for prostate cancer patients and includes 25 items that cover 6 dimensions: (1) PR URI (urinary symptoms, 8 items), (2) PR BOW (bowel symptoms, 4 items), (3) PR HTR (hormonal treatment-related symptoms, 6 items), (4) PR AID (incontinence aid, 1 item), (5) PR SAC (sexually active, 2 items); and (6) PR SFU (sexual function, 4 items). Higher scores on symptom domains (for example., urinary, bowel, etc.) indicate greater symptom burden and higher scores on function domains (for example, Sexual Function) indicate better functioning.

Baseline up to approximately 4 years 5 months
Change from Baseline in HRQoL as Assessed by European Quality of Life Visual Analog Scale (EQ-5D VAS) Score
Zeitfenster: Baseline up to approximately 4 years 5 months

The EQ-5D descriptive system comprises 5 items across the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D includes a visual analog scale (EQ-VAS) that has endpoints labeled "best imaginable health state" and "worst imaginable health state" anchored at 100 and 0, respectively. Here, higher score indicates better quality of life.

Baseline up to approximately 4 years 5 months
Time to Sustained Worsening of Pain as Assessed by BPI-SF
Zeitfenster: Up to approximately 4 years 5 months

Time to sustained worsening of pain will be reported using BPI-SF. The BPI-SF was developed to measure both intensity or severity of pain and pain interference with daily life dimensions. It measures pain intensity via 4 questions, that is, "pain at its worst in the last 24 hours", "pain at its least in the last 24 hours", "pain on the average", and "pain you have right now". The BPI-SF assesses how much pain has interfered with the following 7 activities: general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Higher score indicates more pain.

Up to approximately 4 years 5 months
Treatment Side Effect as Assessed by EORTC IL46 Score
Zeitfenster: Up to approximately 4 years 5 months

The EORTC IL46 is a single question that assesses bother (burden) of treatment. It is rated on a scale from 1 to 4, ranging from "not at all" to "very much".

Up to approximately 4 years 5 months
European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) Scale Score
Zeitfenster: Up to approximately 4 years 5 months

The EQ-5D descriptive system comprises 5 items across the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D-5L uses a 5-point Likert response scale ranging from "No problems" to "Extreme problems". Here, higher score indicates better quality of life.

Up to approximately 4 years 5 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Studienleiter: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

19. Dezember 2025

Primärer Abschluss (Geschätzt)

19. November 2027

Studienabschluss (Geschätzt)

7. Juni 2030

Studienanmeldedaten

Zuerst eingereicht

6. November 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

6. November 2025

Zuerst gepostet (Tatsächlich)

10. November 2025

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

3. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

2. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Ja

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren